Edition:
United Kingdom

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

1.24USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$1.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
172,324
52-wk High
$15.27
52-wk Low
$0.99

Latest Key Developments (Source: Significant Developments)

Clearside Biomedical Appoints George Lasezkay As Interim CEO
Monday, 8 Apr 2019 

April 8 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL APPOINTS DR. GEORGE LASEZKAY AS INTERIM CEO.CLEARSIDE BIOMEDICAL INC - LASEZKAY SUCCEEDS DANIEL H. WHITE.CLEARSIDE BIOMEDICAL INC - BOARD IS INITIATING A SEARCH TO IDENTIFY A PERMANENT CEO.CLEARSIDE BIOMEDICAL INC - WHITE RESIGNED AS PRESIDENT AND CEO AND AS A MEMBER OF BOARD.  Full Article

Clearside Biomedical Posts Q4 Loss Per Share of $0.68
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.68.Q4 EARNINGS PER SHARE ESTIMATE $-0.57 -- REFINITIV IBES DATA.XIPERE NDA ACCEPTED AND ON TRACK FOR OCTOBER 19, 2019 PDUFA DATE.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $40.9 MILLION AS OF DECEMBER 31, 2018.  Full Article

Clearside Biomedical Receives Notification Of FDA Acceptance Of NDA Filing For Xipere
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL RECEIVES NOTIFICATION OF FDA ACCEPTANCE OF NDA FILING FOR XIPERE™ (TRIAMCINOLONE ACETONIDE OPHTHALMIC SUSPENSION) FOR SUPRACHOROIDAL INJECTION WITH PDUFA DATE SET FOR OCTOBER 19, 2019.CLEARSIDE BIOMEDICAL INC - FDA HAS DETERMINED THAT APPLICATION IS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW..  Full Article

Clearside Biomedical Q3 Loss Per Share $0.75
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.75.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.BELIEVES IT WILL HAVE SUFFICIENT RESOURCES TO FUND ITS PLANNED OPERATIONS INTO Q1 OF 2020.  Full Article

Clearside Biomedical announces Sapphire phase 3 study of combination therapy in retinal vein occlusion did not meet its primary endpoint
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES SAPPHIRE PHASE 3 STUDY OF COMBINATION THERAPY IN RETINAL VEIN OCCLUSION DID NOT MEET ITS PRIMARY ENDPOINT.CLEARSIDE BIOMEDICAL INC - FOCUSING RESOURCES ON UVEITIS PROGRAM; NDA FILING EXPECTED Q4 2018.CLEARSIDE BIOMEDICAL - PLAN TO DISCONTINUE CLINICAL DEVELOPMENT OF COMBINATION THERAPY FOR RVO.  Full Article

Clearside Biomedical Q4 Loss Per Share $0.65
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.65.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Clearside Proposes Public Offering Of $75 Mln Of Shares
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CLEARSIDE BIOMEDICAL INC SAYS IT INTENDS TO OFFER AND SELL $75 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.CLEARSIDE BIOMEDICAL INC - ‍INTENDS TO OFFER $75 MILLION SHARES OF ITS COMMON STOCK IN PUBLIC OFFERING​.  Full Article

Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION.CLEARSIDE BIOMEDICAL INC - ‍NOW EXPECTS TO REPORT PRELIMINARY DATA FROM SAPPHIRE TRIAL IN Q4 OF 2018 INSTEAD OF Q1 OF 2019​.CLEARSIDE BIOMEDICAL - ‍IF PRIMARY ENDPOINTS MET IN BOTH TOPAZ AND SAPPHIRE TRIALS, CO EXPECTS TO SEEK AGNOSTIC LABEL IN U.S..  Full Article

Clearside Biomedical Announces Results From Phase 3 Trial Of CLS-TA
Monday, 5 Mar 2018 

March 5 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF CLS-TA IN MACULAR EDEMA ASSOCIATED WITH NON-INFECTIOUS UVEITIS.PRIMARY ENDPOINT ACHIEVED IN PHASE 3 CLINICAL TRIAL OF CLS-TA.ALL KEY SECONDARY ENDPOINTS ACHIEVED IN STUDY.STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROPORTION OF PATIENTS GAINING 15 OR MORE LETTERS IN VISUAL ACUITY IN STUDY.SUPRACHOROIDAL CLS-TA WAS GENERALLY WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED IN TRIAL.EXPECT TO SUBMIT NDA FOR SUPRACHOROIDAL CLS-TA IN PATIENTS WITH MACULAR EDEMA ASSOCIATED WITH UVEITIS TO FDA IN Q4 2018.EVALUATING OPTIONS FOR SUBMISSIONS TO REGULATORY AGENCIES IN TERRITORIES OUTSIDE OF U.S. FOR SUPRACHOROIDAL CLS-TA.  Full Article

Clearside Biomedical Q3 loss per share $0.72
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Clearside Biomedical Inc ::Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.72.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article